The FDA has granted approval to Medtronic to conduct two clinical trials of the company's CoreValve System, an artificial cardiac valve that patients can receive without undergoing open-heart surgery. The company will recruit more than 1,200 patients for the studies, to be conducted at 40 different sites.

Related Summaries